La cadena de opciones muestra datos clave de las opciones de acciones de Polestar Automotive a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Polestar Automotive..

Polestar Automotive (NASDAQ:PSNY) Bolsa, Cadena de Opciones

Polestar Automotive

Polestar Automotive Holding UK PLC operates as an electric vehicle manufacturer. It engages in designing products that are engineered to excite consumers and drive change. Polestar defines market standards in design, technology, and sustainability. Polestar was established as a premium electric car brand by Volvo Cars and Geely Holdings. Polestar has produced two electric performance cars, namely Polestar 1 and Polestar 2. Geographically, it derives a majority of revenue from the United Kingdom.

Equities

News

Guidance

Movers

HAIL

PSNY

Polestar Automotive registra una caída del 10 % en ingresos del tercer trimestre y ajusta su plan de negocios hasta 2027.

Polestar reporta caída de ingresos: Acciones de PSNY se desploman

Markets

General

ARKX

Polestar registra un aumento del 5,3% en las ventas al por menor en el 4T de 2024, pero reporta una caída del 15% en el total anual.

Ventas de Polestar aumentan 5,3% en el 4T, pero caen un 15% en 2024

Polestar Automotive Holding UK Limited - Class A ADS

Polestar Automotive Holding UK PLC

Polestar Automotive Holding UK Limited - Class C-1 ADS (ADW)

Trading Ideas

RFIL

Watching RF Industries; Hearing Zacks Under $10 Newsletter Picks Stock

<p><a href="https://www.fda.gov/medical-devices/medical-device-recalls/early-alert-infusion-pump-issue-baxter">https://www.fda.gov/medical-devices/medical-device-recalls/early-alert-infusion-pump-issue-baxter</a></p>


FDA Announces: As Of June 27, Baxter Has Reported 79 Serious Injuries And Two Deaths Associated With Infusion Pump Issue

WIIM

LNZA

LanzaTech Global shares are trading higher after the company announced it received a grant by the UK government to proposal sustainable aviation fuel production.

<p><strong>Quest Diagnostics Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) delivered a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/n46539510/quest-diagnostics-reports-second-quarter-2025-financial-results-raises-guidance-for-full-year-2025" rel="noreferrer noopener">robust second quarter in 2025</a>, exceeding analyst expectations with strong sales and earnings growth, prompting an upward revision to its full-year guidance.</p>
<p>However, the diagnostic test provider flagged potential headwinds from ongoing tariffs and the significant financial impact if the Protecting Access to Medicare Act (PAMA) is not deferred, setting the stage for a watchful eye on legislative and trade developments.</p>
<p>For the second quarter of 2025, the company reported sales of $2.76 billion, a 15.2% increase year-over-year, exceeding the c<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">onsensus of $2.73 billion</a>. Adjusted earnings reached $2.62 per share, up 11.5%, also surpassing the consensus of $2.58.</p>
<p><strong><em>Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/46102684/could-personalized-medicine-be-your-portfolios-next-big-winner-find-out" rel="noreferrer noopener">Could Personalized Medicine Be Your Portfolio&#8217;s Next Big Winner? Find Out</a></em></strong></p>
<p>&#8220;Demand for our innovative clinical solutions and expanded business from enterprise accounts complemented growth from acquisitions. We also realized productivity gains as we continued to deploy automation and digital technologies across our operations. Given our performance in the quarter and continued utilization trends, we are raising our full-year 2025 guidance,&#8221; said&nbsp;<strong>Jim Davis</strong>, chairman, CEO, and president.</p>
<p>Revenue per requisition decreased by 0.4%, requisition volume increased 16.3% and organic requisition volume improved by 2.1%. Adjusted Operating income increased 17.3% to $466 million, while the margin improved marginally from 16.6% to 16.9%.</p>
<p>During the earnings conference call, a Quest Diagnostics executive indicated that the company experienced some negative impact from tariffs in the second quarter and anticipates this will continue through the third and fourth quarters.</p>
<p>Furthermore, the executive reportedly stated that if the Protecting Access to Medicare Act (PAMA) is not deferred for another year, the financial impact to Quest Diagnostics would be approximately $100 million.</p>
<p>This suggests that Quest Diagnostics is facing a dual challenge: ongoing costs related to current tariffs and a significant potential financial hit if PAMA provisions are not postponed. The company&#8217;s future financial performance will likely be closely tied to developments on both of these fronts.</p>
<p><strong>Outlook:&nbsp;</strong>Quest Diagnostics revised 2025 guidance for revenue from <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44929366/quest-diagnostics-revenue-rebound-strategic-moves-fuel-outlook-confidence" rel="noreferrer noopener">$10.70 billion-$10.85 billion</a> to $10.80 billion-$10.92 billion versus the consensus of $10.79 billion.</p>
<p>The company expects adjusted earnings of $9.63-$9.83 compared to prior guidance of $9.55-$9.80 and the consensus of $9.70.</p>
<p>Reflecting the positive sentiment from the company&#8217;s strong results and raised outlook, investment firm <strong>William Blair </strong>provided its assessment, &#8220;Quest continues to showcase itself as a predictable revenue and earnings grower, and we remain confident in the updated 2025 guide and longer-term targets.&#8221;</p>
<p>Shares are trading at 16 times expected earnings over the next 12 months, slightly above the 10-year average of 15 times. Analyst Andrew F. Brackmann believes this higher valuation is justified due to the sector&#8217;s supportive economic environment, steady revenue and profit growth, and favorable market trends for reference labs. William Blair has reiterated its <a target="_blank" href="https://www.benzinga.com/quote/DGX/analyst-ratings" rel="noreferrer noopener">Outperform</a> rating on the stock.</p>
<p><strong>Price Action:</strong> DGX stock is trading higher by 6.19% to $176.75 at last check Tuesday.</p>
<p><strong>Read Next:</strong></p>
<ul class="wp-block-list">
<li><strong><em><a href="https://www.benzinga.com/markets/earnings/25/07/46546792/mscis-q2-success-fueled-by-record-etf-growth-diverse-client-expansion" target="_blank" rel="noreferrer noopener">MSCI&#8217;s Q2 Success Fueled By Record ETF Growth, Diverse Client Expansion</a></em></strong></li>
</ul>
<p><em>Photo via Shutterstock</em></p>


Analyst Color

Earnings

Health Care

Reiteration

Analyst Ratings

Quest Diagnostics Raises Outlook, But Warns Of Tariff And Medicare Act Risks

<p><a href="https://www.pdports.co.uk/news/brookfield-asset-management-agrees-to-sell-a-49-stake-in-pd-ports/" title="https://www.pdports.co.uk/news/brookfield-asset-management-agrees-to-sell-a-49-stake-in-pd-ports/">https://www.pdports.co.uk/news/brookfield-asset-management-agrees-to-sell-a-49-stake-in-pd-ports/</a></p>


Asset Sales

'Brookfield Asset Management Agrees To Sell A 49% Stake In PD Ports' - PD Ports

<h3>Gainers</h3>
<ul>
<li><strong>Faraday Future</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFAI#NASDAQ">FFAI</a>) stock rose 44.4% to $2.96 during Tuesday's regular session. The company's market cap stands at $202.0 million. </li>
<li><strong>Kohl's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) stock moved upwards by 31.81% to $13.74. The market value of their outstanding shares is at $1.1 billion. </li>
<li><strong>Kirkland's</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIRK#NASDAQ">KIRK</a>) stock increased by 28.74% to $1.84. The company's market cap stands at $32.1 million. </li>
<li><strong>JX Luxventure Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JXG#NASDAQ">JXG</a>) stock moved upwards by 26.66% to $1.33. The company's market cap stands at $4.2 million. </li>
<li><strong>1-800-Flowers.com</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLWS#NASDAQ">FLWS</a>) stock increased by 25.77% to $6.49. The market value of their outstanding shares is at $327.9 million. </li>
<li><strong>Chegg</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHGG#NYSE">CHGG</a>) stock moved upwards by 23.4% to $1.69. The company's market cap stands at $146.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>E-Home Household Service</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EJH#NASDAQ">EJH</a>) shares fell 45.0% to $1.38 during Tuesday's regular session. </li>
<li><strong>Majestic Ideal Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MJID#NASDAQ">MJID</a>) stock declined by 25.18% to $2.17. The market value of their outstanding shares is at $59.4 million. </li>
<li><strong>Happy City Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCHL#NASDAQ">HCHL</a>) stock declined by 11.34% to $4.46. The market value of their outstanding shares is at $96.0 million. </li>
<li><strong>Legacy Education</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LGCY#AMEX">LGCY</a>) shares declined by 10.87% to $10.96. The market value of their outstanding shares is at $152.1 million. </li>
<li><strong>Volcon</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLCN#NASDAQ">VLCN</a>) stock declined by 10.4% to $15.0. The market value of their outstanding shares is at $9.1 million. </li>
<li><strong>Golden Heaven Group Hldgs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDHG#NASDAQ">GDHG</a>) shares fell 9.86% to $0.63. The market value of their outstanding shares is at $26.5 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CHGG

Faraday Future Intelligent Electric Inc. - Class A Common Stock

FFAI

FLWS

GDHG

HCHL

KIRK

LGCY

MJID

VLCN

12 Consumer Discretionary Stocks Moving In Tuesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li><strong>Polyrizon</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock increased by 54.8% to $1.41 during Tuesday's regular session. The company's market cap stands at $4.8 million. </li>
<li><strong>Medpace Hldgs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) shares rose 51.65% to $468.44. The company's market cap stands at $8.8 billion. As per the news, the Q2 earnings report came out yesterday. </li>
<li><strong>Celularity</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) shares increased by 37.06% to $4.32. The market value of their outstanding shares is at $75.4 million. </li>
<li><strong>Fortrea Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) shares moved upwards by 25.75% to $5.86. The market value of their outstanding shares is at $421.9 million. </li>
<li><strong>Psyence Biomedical</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares moved upwards by 23.04% to $6.54. The market value of their outstanding shares is at $3.7 million. </li>
<li><strong>IQVIA Hldgs</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) stock rose 18.58% to $188.5. The company's market cap stands at $27.5 billion. As per the press release, Q2 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Replimune Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) stock declined by 75.5% to $3.02 during Tuesday's regular session. The market value of their outstanding shares is at $950.0 million. </li>
<li><strong>Baird Medical Investment</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDMD#NASDAQ">BDMD</a>) shares declined by 28.44% to $2.19. The market value of their outstanding shares is at $113.2 million. </li>
<li><strong>180 Life Sciences</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) stock decreased by 26.93% to $2.05. The company's market cap stands at $16.9 million. </li>
<li><strong>Autonomix Medical</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) stock declined by 20.9% to $1.45. The company's market cap stands at $7.3 million. </li>
<li><strong>Anbio Biotechnology</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNNN#NASDAQ">NNNN</a>) shares declined by 17.67% to $42.4. The market value of their outstanding shares is at $2.2 billion. </li>
<li><strong>TNF Pharmaceuticals</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) shares decreased by 16.54% to $0.11. The company's market cap stands at $1.8 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


AMIX

ATNF

BDMD

CELU

FTRE

MEDP

NNNN

PLRZ

REPL

TNFA

12 Health Care Stocks Moving In Tuesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li><strong>Dragonfly Energy Hldgs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFLI#NASDAQ">DFLI</a>) shares increased by 93.8% to $0.52 during Tuesday's regular session. The market value of their outstanding shares is at $2.4 million. </li>
<li><strong>Fusion Fuel Green</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTOO#NASDAQ">HTOO</a>) shares moved upwards by 64.34% to $7.03. The company's market cap stands at $3.6 million. </li>
<li><strong>WANG &amp; LEE Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) stock increased by 41.11% to $0.07. The market value of their outstanding shares is at $1.6 million. </li>
<li><strong>ESS Tech</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWH#NYSE">GWH</a>) stock rose 31.4% to $2.05. The company's market cap stands at $20.1 million. </li>
<li><strong>Erayak Power Solution Gr</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAYA#NASDAQ">RAYA</a>) shares rose 19.17% to $0.19. The market value of their outstanding shares is at $7.2 million. </li>
<li><strong>High-Trend International</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTCO#NASDAQ">HTCO</a>) stock increased by 16.65% to $0.25. The company's market cap stands at $26.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>OceanPal</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OP#NASDAQ">OP</a>) shares declined by 20.6% to $0.5 during Tuesday's regular session. The company's market cap stands at $4.7 million. </li>
<li><strong>Knightscope</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KSCP#NASDAQ">KSCP</a>) shares fell 13.3% to $7.5. The market value of their outstanding shares is at $59.6 million. </li>
<li><strong>BlackSky Technology</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKSY#NYSE">BKSY</a>) shares fell 13.13% to $19.4. The market value of their outstanding shares is at $778.2 million. </li>
<li><strong>Toppoint Holdings</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOPP#AMEX">TOPP</a>) shares decreased by 11.27% to $1.75. The company's market cap stands at $34.4 million. </li>
<li><strong>Baiya International Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIYA#NASDAQ">BIYA</a>) stock fell 10.53% to $0.78. The market value of their outstanding shares is at $10.9 million. </li>
<li><strong>Westwater Resources</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/WWR#AMEX">WWR</a>) stock decreased by 10.45% to $0.88. The company's market cap stands at $76.1 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


BIYA

BlackSky Technology Inc. Class A Common Stock

BKSY

DFLI

HTCO

HTOO

KSCP

RAYA

TOPP

WLGS

12 Industrials Stocks Moving In Tuesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li><strong>Lightwave Logic</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LWLG#NASDAQ">LWLG</a>) shares rose 23.3% to $2.54 during Tuesday's regular session. The company's market cap stands at $257.5 million. </li>
<li><strong>Aehr Test System</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHR#NASDAQ">AEHR</a>) shares increased by 21.51% to $19.99. The market value of their outstanding shares is at $489.7 million. </li>
<li><strong>Trident Digital Tech</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDTH#NASDAQ">TDTH</a>) stock increased by 19.99% to $2.4. The company's market cap stands at $129.0 million. </li>
<li><strong>Daqo New Energy</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DQ#NYSE">DQ</a>) stock rose 18.51% to $24.96. The company's market cap stands at $1.3 billion. </li>
<li><strong>Foxx Development Hldgs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXX#NASDAQ">FOXX</a>) shares rose 11.85% to $6.04. The company's market cap stands at $36.6 million. </li>
<li><strong>Mega Fortune Co</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGRT#NASDAQ">MGRT</a>) shares moved upwards by 10.62% to $3.57. The company's market cap stands at $44.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>ReAlpha Tech</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRE#NASDAQ">AIRE</a>) shares declined by 44.9% to $0.47 during Tuesday's regular session. The market value of their outstanding shares is at $47.6 million. </li>
<li><strong>PicoCELA</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCLA#NASDAQ">PCLA</a>) shares declined by 32.12% to $0.53. The market value of their outstanding shares is at $25.9 million. </li>
<li><strong>Cambium Networks</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMBM#NASDAQ">CMBM</a>) shares decreased by 14.71% to $1.16. The company's market cap stands at $38.4 million. </li>
<li><strong>Badger Meter</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMI#NYSE">BMI</a>) stock decreased by 13.4% to $212.38. The market value of their outstanding shares is at $7.2 billion. As per the press release, Q2 earnings came out today. </li>
<li><strong>Ouster</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NASDAQ">OUST</a>) shares decreased by 11.19% to $26.04. The market value of their outstanding shares is at $1.5 billion. </li>
<li><strong>NOVONIX</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVX#NASDAQ">NVX</a>) stock declined by 9.9% to $1.64. The market value of their outstanding shares is at $289.5 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


AEHR

AIRE

CMBM

FOXX

LWLG

MGRT

Nuveen California Dividend Advantage Municipal Fund 2

OUST

PCLA

TDTH

12 Information Technology Stocks Moving In Tuesday's Intraday Session

<p>The U.S. Food and Drug Administration appointed <strong>George F. Tidmarsh</strong> on Monday as director of the Center for <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">Drug Evaluation and Research (CDER)</a>.</p>
<p>Tidmarsh earned his M.D. and Ph.D. in cancer biology from Stanford University, where he completed residency training in pediatrics.</p>
<p>He completed <a href="https://www.fda.gov/news-events/press-announcements/stanford-faculty-member-george-tidmarsh-md-phd-named-director-center-drug-evaluation-and-research" target="_blank" rel="noreferrer noopener">two</a> subspecialty programs at Stanford, one in pediatric oncology and another in neonatology. He brings over 30 years of experience in biotechnology, clinical medicine and regulatory science, and has authored 143 scientific publications and patents. </p>
<p>Tidmarsh is stepping in as the FDA faces major changes under Health and Human Services Secretary <strong>Robert F. Kennedy Jr</strong>.</p>
<p>Kennedy has pushed for <a href="https://www.benzinga.com/general/health-care/25/05/45326217/trumps-hhs-overhaul-faces-legal-blowback-from-states-over-deep-staffing-cuts-slashed-programs" target="_blank" rel="noreferrer noopener">large staff cuts at HHS</a> and has hired some people who share his <a href="https://www.benzinga.com/markets/25/03/44550801/rfk-jr-spreading-misinformation-and-lies-fdas-top-vaccine-official-walks-out-sparking-debate-on-safety-and-public-trust">doubts about vaccines</a>.</p>
<p><strong>Also Read: <a href="https://www.benzinga.com/news/health-care/25/07/46219622/trump-administrations-health-agency-overstepped-authority-reorganization-unlawful-court" target="_blank" rel="noreferrer noopener">Trump&#8217;s HHS Overhaul Faces Legal Blowback From States Over Deep Staffing Cuts, Slashed Health Programs</a></strong></p>
<p>Still, the pharmaceutical industry may feel some relief with Tidmarsh&#8217;s appointment. He has a strong background in drug development, having helped bring seven approved drugs to market. However, his past remarks suggest he might take a tougher stance on drug regulation.</p>
<p>Citing an opinion piece published in April, CNBC <a href="https://www.cnbc.com/2025/07/21/fda-george-tidmarsh-as-rfk-jr-top-drug-regulator.html" target="_blank" rel="noreferrer noopener">says</a> Tidmarsh criticized decisions made by Peter Marks, a top FDA official removed under Kennedy. Tidmarsh opposed the fast-tracking of <strong>Biogen Inc&#8217;s</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) controversial Alzheimer&#8217;s drug Aduhelm and disagreed with the decision to expand approval for <strong>Sarepta Therapeutics Inc&#8217;s</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) muscular dystrophy drug Elevidys, which overruled FDA staff.</p>
<p>Tidmarsh&#8217;s appointment &#8220;brings in a generally well-respected, credible industry veteran, we believe helping fill a key regulatory void,&#8221; Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-07-21/fda-to-name-biotech-executivey-george-tidmarsh-as-rfk-jr-s-top-drug-regulator" rel="noreferrer noopener">wrote</a>, citing Brian Abrahams, an analyst at RBC Capital Markets.</p>
<p>While recent cuts at the agency have raised concerns about the FDA&#8217;s drug approval process, &#8220;we would expect Tidmarsh to be a pragmatic officer who will likely build upon current practice to ensure continuity and potentially be an advocate for the industry.&#8221;</p>
<p>The Bloomberg report added that one of the big challenges facing Tidmarsh is the FDA's accelerated drug approval process. This faster track for getting drugs approved has become more common in recent years. While supporters say it helps patients with serious illnesses get treatments faster, critics argue it allows some unproven drugs to stay on the market for too long.</p>
<p>Tidmarsh is also expected to play a major role in rethinking how the agency regulates prescription drug advertising. Kennedy Jr. has been outspoken against drug ads aimed at consumers, and agency official Marty Makary said the current rules are under review.</p>
<p>Last year, at a Stanford panel on censorship and scientific speech, Tidmarsh criticized the FDA for being inconsistent in regulating drugs.</p>
<p>He pointed out the agency's strict rules on how drugmakers can talk about off-label uses and questioned some vaccine ads shown during the COVID-19 pandemic.</p>
<p><strong>Read Next:</strong></p>
<p><strong><a href="https://www.benzinga.com/markets/large-cap/25/07/46525621/roper-tech-lifts-2025-outlook-as-ai-acquisitions-fuel-double-digit-growth" target="_blank" rel="noreferrer noopener">Roper Tech Lifts 2025 Outlook As AI, Acquisitions Fuel Double-Digit Growth</a></strong></p>
<p><em>Photo: jittawit21 via Shutterstock</em></p>


Biotech

Government

Management

BIIB

SRPT

FDA Names Biotech Veteran George Tidmarsh To Lead Drug Evaluation Division

<p><a href="https://www.sprucepointcap.com/research/an-overheated-hvac-growth-story" title="https://www.sprucepointcap.com/research/an-overheated-hvac-growth-story">https://www.sprucepointcap.com/research/an-overheated-hvac-growth-story</a></p>


Short Sellers

Watching Limbach Holdings; Spruce Point Capital Issues Report On The Co Stating They Are Short

DDC Enterprise shares are trading higher. The company announced a $500 million mixed shelf offering.

<ul>
<li>Clinical efficacy and safety data will be presented from over 70 small-cell lung cancer (SCLC) patients in Hengrui's ongoing, multi-site, open label Phase 1 trial</li>
<li>Data will include patients from the dose escalation and at multiple expansion doses</li>
<li>U.S. Phase 1 trial of IDE849 in SCLC patients initiated in 3Q 2025</li>
</ul>
<p>JIANGSU, China and SOUTH SAN FRANCISCO, Calif., July 22, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDYA#NASDAQ">IDYA</a>), a leading precision medicine oncology company, and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui), a global pharmaceutical company focused on scientific and technological innovation, today announced the publication of an abstract for an oral presentation on IDE849 (SHR-4849) at the IASLC 2025 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (WCLC), taking place September 6-9, 2025 in Barcelona, Spain. The presentation will cover efficacy and safety results in&nbsp;SCLC from the Phase 1 trial Hengrui is conducting in China for IDE849 (SHR-4849), a potential first-in-class delta-like ligand 3 (DLL3)-targeting Topoisomerase-1 (TOP1) payload antibody drug conjugate (ADC). DLL3 is&nbsp;upregulated across multiple solid tumor types where significant unmet need remains, including SCLC, neuroendocrine tumors (NETs), non-small cell lung cancer (NSCLC) and melanoma.&nbsp;</p>


IDYA

IDEAYA Biosciences To Present Clinical Efficacy And Safety Data From Over 70 Small-Cell Lung Cancer Patients In Hengrui's Ongoing, Multi-Site, Open Label Phase 1 Trial, At IASLC 2025 World Conference

<p><strong>Oceaneering International</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OII#NYSE">OII</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-07-23. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Oceaneering International will report an <strong>earnings per share</strong> (EPS) of $0.41. </p>
<p>Anticipation surrounds Oceaneering International's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Past Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS beat by $0.12, leading to a 3.76% increase in the share price on the subsequent day.</p>
<p>Here's a look at Oceaneering International's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.31</td>
<td>0.41</td>
<td>0.44</td>
<td>0.30</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.43</td>
<td>0.37</td>
<td>0.36</td>
<td>0.28</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>4.0%</td>
<td>-4.0%</td>
<td>6.0%</td>
<td>14.000000000000002%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753203771_0.png" alt="eps graph" /></p>
<h3>Market Performance of Oceaneering International's Stock</h3>
<p>Shares of Oceaneering International were trading at $20.77 as of July 21. Over the last 52-week period, shares are down 16.46%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analyst Insights on Oceaneering International</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Oceaneering International.</p>
<p>Analysts have given Oceaneering International a total of 1 ratings, with the consensus rating being Neutral. The average one-year price target is $21.0, indicating a potential 1.11% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of Liberty Energy, Tidewater and Flowco Holdings, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Liberty Energy, with an average 1-year price target of $14.75, suggesting a potential 28.98% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Tidewater, with an average 1-year price target of $70.0, suggesting a potential 237.02% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Flowco Holdings, with an average 1-year price target of $32.5, suggesting a potential 56.48% upside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
<p>The peer analysis summary provides a snapshot of key metrics for Liberty Energy, Tidewater and Flowco Holdings, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oceaneering International</td>
<td>Neutral</td>
<td>12.59%</td>
<td>$135.01M</td>
<td>6.77%</td>
</tr>
<tr>
<td>Liberty Energy</td>
<td>Neutral</td>
<td>-8.91%</td>
<td>$88.10M</td>
<td>1.02%</td>
</tr>
<tr>
<td>Tidewater</td>
<td>Outperform</td>
<td>3.82%</td>
<td>$101.60M</td>
<td>3.83%</td>
</tr>
<tr>
<td>Flowco Holdings</td>
<td>Outperform</td>
<td>188.33%</td>
<td>$65.81M</td>
<td>2.63%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Oceaneering International ranks in the middle among its peers for Consensus rating. It ranks at the bottom for Revenue Growth and Gross Profit, but at the top for Return on Equity.</p>
<h3>All You Need to Know About Oceaneering International</h3>
<p>Oceaneering International Inc is a provider of engineered services and products and robotic solutions to the offshore energy, defense, aerospace, manufacturing, and entertainment industries. A majority of its products are produced for the offshore oil and gas market. The company's business segments are Integrity Management and Digital Solutions, Subsea Robotics, Manufactured Products, Offshore Projects Group, and Aerospace and Defense Technologies. Maximum revenue is generated from its Subsea Robotics segment, which provides remotely operated vehicles (ROVs) for drill support and vessel-based services, underwater surveys, tooling, and other activities. Geographically, the company derives its key revenue from the United States, followed by Africa, Norway, Brazil, and other regions.</p>
<h3>A Deep Dive into Oceaneering International's Financials</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Oceaneering International's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately <strong>12.59%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Energy sector.</p>
<p><strong>Net Margin:</strong> Oceaneering International's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>7.47%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Oceaneering International's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>6.77%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Oceaneering International's ROA excels beyond industry benchmarks, reaching <strong>2.18%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Oceaneering International's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>1.08</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<p><a href="https://www.benzinga.com/quote/OII/earnings"><strong>To track all earnings releases for Oceaneering International visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Oceaneering International's Earnings Outlook

<p>Meritage Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTH#NYSE">MTH</a>) will release its quarterly earnings report on Wednesday, 2025-07-23. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Meritage Homes to report an <strong>earnings per share</strong> (EPS) of $2.01.</p>
<p>Investors in Meritage Homes are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Overview of Past Earnings</h3>
<p>During the last quarter, the company reported an EPS beat by $0.01, leading to a 1.04% increase in the share price on the subsequent day.</p>
<p>Here's a look at Meritage Homes's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.68</td>
<td>2.20</td>
<td>2.48</td>
<td>2.59</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.69</td>
<td>2.36</td>
<td>2.67</td>
<td>3.16</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>3.0%</td>
<td>-2.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753203762_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Meritage Homes were trading at $69.95 as of July 21. Over the last 52-week period, shares are down 21.36%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<h3>Insights Shared by Analysts on Meritage Homes</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Meritage Homes.</p>
<p>Analysts have provided Meritage Homes with 3 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $76.33, suggesting a potential 9.12% upside.</p>
<h3>Comparing Ratings with Competitors</h3>
<p>The analysis below examines the analyst ratings and average 1-year price targets of Installed Building Prods, Taylor Morrison Home and KB Home, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Installed Building Prods, with an average 1-year price target of $192.5, suggesting a potential 175.2% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Taylor Morrison Home, with an average 1-year price target of $74.67, suggesting a potential 6.75% upside.</li>
<li>Analysts currently favor an Neutral trajectory for KB Home, with an average 1-year price target of $58.25, suggesting a potential 16.73% downside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
<p>The peer analysis summary provides a snapshot of key metrics for Installed Building Prods, Taylor Morrison Home and KB Home, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meritage Homes</td>
<td>Neutral</td>
<td>-7.17%</td>
<td>$302.38M</td>
<td>2.38%</td>
</tr>
<tr>
<td>Installed Building Prods</td>
<td>Buy</td>
<td>-1.17%</td>
<td>$223.70M</td>
<td>6.65%</td>
</tr>
<tr>
<td>Taylor Morrison Home</td>
<td>Outperform</td>
<td>11.55%</td>
<td>$463.27M</td>
<td>3.61%</td>
</tr>
<tr>
<td>KB Home</td>
<td>Neutral</td>
<td>-10.54%</td>
<td>$297.96M</td>
<td>2.65%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>In terms of consensus rating, Meritage Homes is rated in the middle compared to its peers. It ranks at the bottom for revenue growth among the group. However, it has the highest gross profit. When it comes to return on equity, Meritage Homes is positioned in the middle range.</p>
<h3>Delving into Meritage Homes's Background</h3>
<p>Meritage Homes Corp is engaged as a designer and builder of single-family attached and detached homes. It has operations in three regions: West, Central, and East, comprising ten states: Arizona, California, Colorado, Texas, Florida, Georgia, North Carolina, South Carolina, Tennessee, and Utah. The company operates with two principal business segments: homebuilding and financial services. The homebuilding segments are engaged in the business of acquiring and developing land, constructing homes, marketing and selling those homes, and providing warranty and customer services, and the financial services segment offers title and escrow, mortgage, and insurance services. The company generates key revenue from the homebuilding segment.</p>
<h3>Key Indicators: Meritage Homes's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Challenges:</strong> Meritage Homes's revenue growth over 3 months faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately <strong>-7.17%</strong>. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Meritage Homes's net margin is impressive, surpassing industry averages. With a net margin of <strong>8.99%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>2.38%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Meritage Homes's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>1.65%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.36</strong>, Meritage Homes adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<p><a href="https://www.benzinga.com/quote/MTH/earnings"><strong>To track all earnings releases for Meritage Homes visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Meritage Homes's Earnings: A Preview

<p>M/I Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MHO#NYSE">MHO</a>) is preparing to release its quarterly earnings on Wednesday, 2025-07-23. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect M/I Homes to report an <strong>earnings per share</strong> (EPS) of $4.43.</p>
<p>The announcement from M/I Homes is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Earnings Track Record</h3>
<p>In the previous earnings release, the company missed EPS by $0.18, leading to a 1.74% increase in the share price the following trading session.</p>
<p>Here's a look at M/I Homes's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>4.16</td>
<td>4.83</td>
<td>4.94</td>
<td>4.59</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>3.98</td>
<td>4.71</td>
<td>5.10</td>
<td>5.12</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>2.0%</td>
<td>1.0%</td>
<td>-1.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753203753_0.png" alt="eps graph" /></p>
<h3>Tracking M/I Homes's Stock Performance</h3>
<p>Shares of M/I Homes were trading at $114.28 as of July 21. Over the last 52-week period, shares are down 20.53%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analyst Views on M/I Homes</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on M/I Homes.</p>
<p>A total of 1 analyst ratings have been received for M/I Homes, with the consensus rating being Buy. The average one-year price target stands at $140.0, suggesting a potential 22.51% upside.</p>
<h3>Comparing Ratings Among Industry Peers</h3>
<p>The following analysis focuses on the analyst ratings and average 1-year price targets of Tri Pointe Homes, Cavco Indus and Green Brick Partners, three prominent industry players, providing insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Outperform trajectory for Tri Pointe Homes, with an average 1-year price target of $43.0, suggesting a potential 62.37% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Cavco Indus, with an average 1-year price target of $550.0, suggesting a potential 381.27% upside.</li>
<li>Analysts currently favor an Buy trajectory for Green Brick Partners, with an average 1-year price target of $71.0, suggesting a potential 37.87% downside.</li>
</ul>
<h3>Insights: Peer Analysis</h3>
<p>The peer analysis summary offers a detailed examination of key metrics for Tri Pointe Homes, Cavco Indus and Green Brick Partners, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>M/I Homes</td>
<td>Buy</td>
<td>-6.75%</td>
<td>$252.78M</td>
<td>3.74%</td>
</tr>
<tr>
<td>Tri Pointe Homes</td>
<td>Outperform</td>
<td>-21.13%</td>
<td>$178.30M</td>
<td>1.92%</td>
</tr>
<tr>
<td>Cavco Indus</td>
<td>Neutral</td>
<td>21.00%</td>
<td>$116.12M</td>
<td>3.42%</td>
</tr>
<tr>
<td>Green Brick Partners</td>
<td>Buy</td>
<td>11.24%</td>
<td>$155.78M</td>
<td>4.62%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>M/I Homes ranks at the top for Gross Profit and Return on Equity among its peers. It is in the middle for Revenue Growth.</p>
<h3>Unveiling the Story Behind M/I Homes</h3>
<p>M/I Homes Inc is an American construction company that focuses on residential construction. It consists of two distinct operations: homebuilding and financial services. The homebuilding operations are spread into the Midwest, Mid-Atlantic, and Southern regions, and the financial services operations support homebuilding operations by providing mortgage loans and title services to the customers of homebuilding operations. Homebuilding operations comprise a predominant portion of the revenue. The company builds homes and communities that target entry-level, move-up, and luxury homebuyers.</p>
<h3>M/I Homes's Financial Performance</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> M/I Homes's revenue growth over a period of 3 months has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately <strong>-6.75%</strong>. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> M/I Homes's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>11.4%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> M/I Homes's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>3.74%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> M/I Homes's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>2.44%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.33</strong>, M/I Homes adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<p><a href="https://www.benzinga.com/quote/MHO/earnings"><strong>To track all earnings releases for M/I Homes visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Look Ahead: M/I Homes's Earnings Forecast

<p>Lamb Weston Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>) is preparing to release its quarterly earnings on Wednesday, 2025-07-23. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Lamb Weston Hldgs to report an <strong>earnings per share</strong> (EPS) of $0.64.</p>
<p>Lamb Weston Hldgs bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company beat EPS by $0.23, which was followed by a 0.96% drop in the share price the next day.</p>
<p>Here's a look at Lamb Weston Hldgs's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2025</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.87</td>
<td>1.01</td>
<td>0.72</td>
<td>1.26</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.10</td>
<td>0.66</td>
<td>0.73</td>
<td>0.78</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>-1.0%</td>
<td>3.0%</td>
<td>-6.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753203743_0.png" alt="eps graph" /></p>
<h3>Tracking Lamb Weston Hldgs's Stock Performance</h3>
<p>Shares of Lamb Weston Hldgs were trading at $48.04 as of July 21. Over the last 52-week period, shares are down 13.62%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analyst Opinions on Lamb Weston Hldgs</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Lamb Weston Hldgs.</p>
<p>The consensus rating for Lamb Weston Hldgs is Neutral, based on 4 analyst ratings. With an average one-year price target of $59.5, there's a potential 23.86% upside.</p>
<h3>Peer Ratings Overview</h3>
<p>The analysis below examines the analyst ratings and average 1-year price targets of Post Holdings, Cal-Maine Foods and Conagra Brands, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Outperform trajectory for Post Holdings, with an average 1-year price target of $129.0, suggesting a potential 168.53% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Cal-Maine Foods, with an average 1-year price target of $101.67, suggesting a potential 111.64% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Conagra Brands, with an average 1-year price target of $21.93, suggesting a potential 54.35% downside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
<p>The peer analysis summary outlines pivotal metrics for Post Holdings, Cal-Maine Foods and Conagra Brands, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lamb Weston Hldgs</td>
<td>Neutral</td>
<td>4.27%</td>
<td>$422.50M</td>
<td>8.94%</td>
</tr>
<tr>
<td>Post Holdings</td>
<td>Outperform</td>
<td>-2.35%</td>
<td>$545.80M</td>
<td>1.62%</td>
</tr>
<tr>
<td>Cal-Maine Foods</td>
<td>Neutral</td>
<td>101.64%</td>
<td>$716.12M</td>
<td>22.97%</td>
</tr>
<tr>
<td>Conagra Brands</td>
<td>Neutral</td>
<td>-4.27%</td>
<td>$707.20M</td>
<td>2.89%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Lamb Weston Hldgs ranks in the middle for Consensus rating. It is at the bottom for Revenue Growth and Gross Profit, but at the top for Return on Equity among its peers.</p>
<h3>Unveiling the Story Behind Lamb Weston Hldgs</h3>
<p>Lamb Weston is North America's largest and the world's second-largest producer of branded and private-label frozen potato products, both by volume and value. The company's portfolio is anchored by french fries, but it also sells sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. Roughly two thirds of revenue comes from its home market of North America, with none of the other 100 countries the company sells into representing a significant share. McDonald's is Lamb Weston's single-largest customer at 14% of fiscal 2024 sales, with no other company representing more than 10%. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.</p>
<h3>Breaking Down Lamb Weston Hldgs's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Lamb Weston Hldgs's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>4.27%</strong> as of 28 February, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Staples sector.</p>
<p><strong>Net Margin:</strong> Lamb Weston Hldgs's net margin is impressive, surpassing industry averages. With a net margin of <strong>9.6%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Lamb Weston Hldgs's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>8.94%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Lamb Weston Hldgs's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>1.96%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Lamb Weston Hldgs's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>2.61</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<p><a href="https://www.benzinga.com/quote/LW/earnings"><strong>To track all earnings releases for Lamb Weston Hldgs visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Examining the Future: Lamb Weston Hldgs's Earnings Outlook

<p>Rogers Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCI#NYSE">RCI</a>) is preparing to release its quarterly earnings on Wednesday, 2025-07-23. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Rogers Communications to report an <strong>earnings per share</strong> (EPS) of $0.80.</p>
<p>The market awaits Rogers Communications's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Earnings Track Record</h3>
<p>In the previous earnings release, the company missed EPS by $0.02, leading to a 0.64% increase in the share price the following trading session.</p>
<p>Here's a look at Rogers Communications's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.71</td>
<td>0.95</td>
<td>0.98</td>
<td>0.84</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.69</td>
<td>1.04</td>
<td>1.04</td>
<td>0.85</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>-4.0%</td>
<td>-2.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753203724_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Rogers Communications were trading at $33.32 as of July 21. Over the last 52-week period, shares are down 8.16%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/RCI/earnings"><strong>To track all earnings releases for Rogers Communications visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Preview: Rogers Communications's Earnings

FAST

CNBC Halftime Report Final Trades: Rocket Companies, Toll Brothers, Fastenal Company, CBOE Volatility Index

<p><strong>Hasbro</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAS#NASDAQ">HAS</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-07-23. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Hasbro will report an <strong>earnings per share</strong> (EPS) of $0.77. </p>
<p>Investors in Hasbro are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company beat EPS by $0.37, which was followed by a 1.03% increase in the share price the next day.</p>
<p>Here's a look at Hasbro's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.67</td>
<td>0.35</td>
<td>1.28</td>
<td>0.78</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.04</td>
<td>0.46</td>
<td>1.73</td>
<td>1.22</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>-2.0%</td>
<td>0.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753203714_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Hasbro were trading at $77.67 as of July 21. Over the last 52-week period, shares are up 30.26%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analysts' Perspectives on Hasbro</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Hasbro.</p>
<p>A total of 8 analyst ratings have been received for Hasbro, with the consensus rating being Buy. The average one-year price target stands at $76.75, suggesting a potential 1.18% downside.</p>
<h3>Analyzing Analyst Ratings Among Peers</h3>
<p>The analysis below examines the analyst ratings and average 1-year price targets of Mattel, Acushnet Holdings and Brunswick, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Mattel, with an average 1-year price target of $22.8, suggesting a potential 70.65% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Acushnet Holdings, with an average 1-year price target of $74.2, suggesting a potential 4.47% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Brunswick, with an average 1-year price target of $56.2, suggesting a potential 27.64% downside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
<p>The peer analysis summary presents essential metrics for Mattel, Acushnet Holdings and Brunswick, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hasbro</td>
<td>Buy</td>
<td>17.14%</td>
<td>$625.60M</td>
<td>8.47%</td>
</tr>
<tr>
<td>Mattel</td>
<td>Buy</td>
<td>2.11%</td>
<td>$408.10M</td>
<td>-1.84%</td>
</tr>
<tr>
<td>Acushnet Holdings</td>
<td>Neutral</td>
<td>-0.59%</td>
<td>$337.16M</td>
<td>12.86%</td>
</tr>
<tr>
<td>Brunswick</td>
<td>Neutral</td>
<td>-10.49%</td>
<td>$303.90M</td>
<td>1.07%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Hasbro ranks highest in revenue growth among its peers. It also leads in gross profit margin. However, it has the lowest return on equity compared to the others.</p>
<h3>Delving into Hasbro's Background</h3>
<p>Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. The firm acquired EOne in 2019, bolting on popular family properties like Peppa Pig and PJ Masks, and since has divested noncore lines from the tie-up. Furthermore, the addition of Dungeons &amp; Dragons Beyond in 2022, offers the firm access to 19 million digital tabletop players.</p>
<h3>Financial Milestones: Hasbro's Journey</h3>
<p><strong>Market Capitalization:</strong> Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Hasbro showcased positive performance, achieving a revenue growth rate of <strong>17.14%</strong> as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Hasbro's net margin is impressive, surpassing industry averages. With a net margin of <strong>11.11%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Hasbro's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>8.47%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Hasbro's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>1.59%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Hasbro's debt-to-equity ratio surpasses industry norms, standing at <strong>2.87</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<p><a href="https://www.benzinga.com/quote/HAS/earnings"><strong>To track all earnings releases for Hasbro visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Hasbro's Earnings Outlook

Press Releases

Polestar Q1 retail sales grew by 76% compared to the same quarter last year

Polestar Annual Sustainability Report announces a 25% cut in emissions per sold car

Polestar provides updates on financial guidance for 2025 and 2024 20-F

Polestar Sets the Date for Q1 2025 Select Results

Polestar reports Q1 2025 revenue growth of 84% and significant gross margin improvement to positive

Polestar Sets Date for AGM and Announces Board Changes

Polestar announces USD 200 million equity investment

European production of Polestar 7 confirmed in Kosice, Slovakia

Polestar retail sales volumes totalled 18,049 cars in Q2, a growth of 38% year-on-year

Agero Helps Polestar Deliver Industry-Leading Roadside Assistance to EV Owners

AYRO

Cenntro

Chijet Motor Company, Inc. - Ordinary Shares

Chijet Motor Co

ECD Automotive Design, Inc. - Common Stock

ECD Automotive Design

Envirotech Vehicles

Ford Motor

Faraday Future

Fly-E Group

General Motors

Honda Motor Co

Lucid Group

Li Auto Inc. - American Depositary Shares

Li Auto

Lotus Technology Inc. - American Depositary Shares

Lotus Technology

NIO Inc. American depositary shares, each representing one Class A ordinary share

NWTN

Rivian Automotive, Inc. - Class A Common Stock

Rivian Automotive

Thor Industries

Toyota Motor

Tesla

VinFast Auto

Winnebago Industries

Workhorse Gr

XPeng Inc. American depositary shares, each representing two Class A ordinary shares

XPeng

ZEEKR Intelligent Technology Holding Limited American Depositary Shares (each representing ten (10) Ordinary Shares)

Comments

Polestar Automotive

Polestar Automotive (PSNY) Opciones

Polestar Automotive (NASDAQ:PSNY) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL